FDA Acne Guidance Recommends Selection Of Lesion Type Prior To Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors developing acne drugs should specify the type of lesion an investigational drug is intended to treat prior to beginning Phase III studies, FDA recommends in a recent draft guidance.